{"meshTags":["Adenocarcinoma","Adult","Disease Progression","Drug Eruptions","Erlotinib Hydrochloride","Female","Humans","Lung Neoplasms","Male","Middle Aged","Protein Kinase Inhibitors","Quinazolines"],"meshMinor":["Adenocarcinoma","Adult","Disease Progression","Drug Eruptions","Erlotinib Hydrochloride","Female","Humans","Lung Neoplasms","Male","Middle Aged","Protein Kinase Inhibitors","Quinazolines"],"genes":["epidermal growth factor receptor-tyrosine kinase","Epidermal growth factor receptor","EGFR","EGFR-TKI","EGFR-TKI"],"publicationTypes":["Case Reports","Journal Article"],"abstract":"Epidermal growth factor receptor (EGFR)--tyrosine kinase inhibitors (TKI) like erlotinib and gefitinib have been approved as monotherapy for the treatment of patients with locally advanced or metastatic non small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. The use of EGFR-TKI is associated with unique and dramatic dermatologic side effects. We report 2 patients with NSCLC developing a typical acneiform (papulo-pustular) eruption shortly after initiation of EGFR-TKI.","title":"Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.","pubmedId":"22822651"}